# VESPER (NCT01812369)

> Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: GC
- Indication: locally advanced bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01812369
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: University Hospital, Rouen
- Conditions: Bladder Cancer
- Interventions: GEMCITABINE CISPLATINE; METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
- Enrollment: 500
- Primary outcome: Progression-free survival (PFS) at 3 years

## Questions raised in the commentary

_Automated from the 40 newest of 67 indexed sources (Jun 2023 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether ddMVAC is the preferred neoadjuvant regimen
- How treatment duration should be chosen
- How ddMVAC tolerability and patient suitability should shape regimen choice
- Whether the neoadjuvant survival signal is sufficient to guide treatment

Also discussed: molecular subtyping.

## Indexed commentary on VESPER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 59
- YouTube: 4
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=vesper-nct01812369

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01812369", "email": "<work email>"}; the inbox owner confirms by the emailed link.